SQShenhong Qu

Shenhong Qu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shenhong Qu has a total of 130 co-authors. Here are the top co-authors by number of shared publications:

  • Min Li

    Department of Otolaryngology & Head and Neck The People's Hospital of Guangxi Zhuang Autonomous Region Nanning China

    19 shared publications
  • Jiazhang Wei

    Department of Otolaryngology & Head and Neck The People's Hospital of Guangxi Zhuang Autonomous Region Nanning China

    13 shared publications
  • Jingjin Weng

    Department of Otolaryngology & Head and Neck The People's Hospital of Guangxi Zhuang Autonomous Region Nanning China

    13 shared publications
  • Fei Liu

    Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology Xi'an Jiaotong University Xi'an China

    12 shared publications
  • Jingjin Weng

    Department of Otolaryngology & Head and Neck, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

    6 shared publications
  • Weiming Deng

    Department of Otolaryngology & Head and Neck The People's Hospital of Guangxi Zhuang Autonomous Region Nanning China

    6 shared publications

Latest Publications

  • Open Access

    Validation of the 9th Edition of the Tumor‐Node‐Metastasis Staging System for Non‐Metastatic Nasopharyngeal Carcinoma: A Multicenter Retrospective Analysis From High‐Incidence Regions

    by Yongquan Wei, Danxue Qin, Baoqing Yang, Bin Deng, Qianxian Luo, Lihong Huang, Jiazhang Wei, Shaojie Zhang, Weiming Deng, Guiping Lan, et al.

    Objective: To evaluate and compare the prognostic value of the 8th and 9th editions of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system in patients with non‐metastatic nasopharyngeal carcinoma (NPC). Methods: Clinical data from 470 patients with NPC treated between November 2019 and June 2022 were retrospectively analyzed. Patients were restaged according to the 8th and 9th editions of the AJCC/UICC staging system. OS was the primary endpoint; locoregional recurrence–free survival (LRFS), distant metastasis–free survival (DMFS), and disease‐free survival (DFS) were secondary endpoints. Kaplan–Meier curves were compared using global and pairwise log‐rank tests. Prognostic discriminative ability was evaluated using the concordance index (C‐index) and Akaike information criterion (AIC). Results: Seventeen patients (3.6%) classified as T3 by TNM‐8 were reclassified as T4 by TNM‐9. Thirty‐one patients (6.6%) were reclassified to N3 because of advanced iENE. TNM‐9 improved discrimination for DMFS across N categories (log‐rank p < 0.001 vs. p = 0.016 for TNM‐8) and for OS ( p < 0.001 vs. p = 0.042). T categories discriminated LRFS in both editions ( p = 0.012 for each), whereas OS differences were not significant (TNM‐8 p = 0.139; TNM‐9 p = 0.137). TNM‐9 overall stage discriminated OS ( p = 0.002), unlike TNM‐8 ( p = 0.121). Both editions discriminated DFS (both p < 0.001), but TNM‐9 provided better pairwise separation between early and advanced overall stages. The 9th edition exhibited enhanced predictive performance compared with the 8th edition, as evidenced by higher C‐index values and lower Akaike information criterion (AIC) values for both DFS and OS prediction across overall stages. Conclusion: The 9th edition of the AJCC/UICC staging system demonstrated superior prognostic discriminative ability compared with the 8th edition, enabling more accurate risk stratification and supporting more informed clinical decision‐making for patients with NPC.

  • Open Access

    Mendelian randomization analysis of the causal relationship between allergic rhinitis and depression and underlying mediation mechanisms

    by Shaojie Zhang, Rong Wang, Jingjin Weng, Min Li, Min Shi, Jiazhang Wei, Linsong Ye, Xueying Huang, Wenlin Huang, Shenhong Qu

  • Open Access

    Construction and validation of a lncRNA/circRNA-miRNA-mRNA ceRNA network in allergic rhinitis pathogenesis

    by Shaojie Zhang, Molu Ban, Rong Wang, Min Li, Min Shi, Jingjin Weng, Shenhong Qu

    The lncRNA/circRNA-miRNA-mRNA interaction constructs a competing endogenous RNAs (ceRNAs) network, which is closely related to inflammation. However, their

  • Open Access

    Identification and phased de novo mutation of the EPS8L2 gene in a patient with progressive hearing loss: A case report

    by Hanxiao Gan, Yu Lu, Shenhong Qu, Lianli Lu, Huilan Xu, Mingyin Fan, Jie Tang, Jinying Mo, Ruichun Chen, Fengzhu Tang

    Pathogenic variants in the EPS8L2 gene are known to underlie nonsyndromic progressive hearing loss. In this study, we enrolled a 39-year-old male patient with deafness. We collected detailed clinical characteristics and results of auxiliary examinations, followed by whole-genome sequencing to analyze 189 genes commonly associated with hereditary deafness. Sanger sequencing and T/A cloning were employed to validate candidate variants, leading to the identification of 2 frameshift mutations in the EPS8L2 gene in a compound heterozygous state and in trans: c.357_361dupGGTGC (p.Gln121Argfs67) and c.1317dupG (p.Leu440Alafs63). Notably, the c.357_361dupGGTGC variant was a de novo mutation in the patient, whereas c.1317dupG was inherited from his mother. Both novel frameshift mutations are predicted to result in severely truncated proteins, and the affected amino acid residues are highly conserved across diverse species. To date, only 2 cases of EPS8L2-associated hearing loss caused by homozygous pathogenic variants have been reported in a single family. Herein, we describe the first case of nonsyndromic autosomal recessive hearing loss 106 (DFNB106) harboring compound heterozygous pathogenic variants in EPS8L2. These findings expand the mutational spectrum of EPS8L2, provide critical insights for genetic diagnosis, genetic counseling, and prognosis assessment of progressive hearing loss caused by EPS8L2 variants, and further offer a clinical reference for identifying de novo compound heterozygous mutations in autosomal recessive nonsyndromic hearing loss (DFNB106) cases, aiding in more accurate etiological identification and targeted management of similar progressive hearing loss patients.

  • Open Access

    The Positive Feedback of lncRNA ANRIL / miRNA ‐339‐5p/ ZBTB7A Suppresses Metastasis of Nasopharyngeal Carcinoma Cells via SREBP1 ‐ FASN

    by Fei Liu, Jiazhang Wei, Suosu Wei, Mingzheng Mo, Jiao Lan, Jingjin Weng, Ruiping Xiao, Cheng Su, Weiming Deng, Yujuan Huang, et al.

    Disruptions in lipid metabolism can hasten disease progression and impose a heavier burden on patients with nasopharyngeal carcinoma (NPC). We previously observed a positive correlation between zinc finger and BTB domain‐containing protein 7A (ZBTB7A) and the long non‐coding RNA antisense non‐coding RNA in the INK4 locus (ANRIL), indicating a potential link between NPC and lipid metabolism; however, the underlying mechanism remains unclear. This study investigated primary NPC tissues that had significantly lower ZBTB7A expression than that in normal nasopharyngeal epithelium. Subsequent results confirmed that ANRIL promoted ZBTB7A expression by sponging miR‐339‐5p. ZBTB7A directly promoted ANRIL expression but inhibited SREBP1 and FASN expression. Thus, the ANRIL/miR‐339‐5p/ZBTB7A axis creates a positive feedback loop that suppresses the lipid pathway. Combining stable ANRIL overexpression with ZBTB7A shRNA effectively reduced lipid metabolism and the migratory, invasive, and metastatic capacities of NPC cells in vitro and in vivo. Furthermore, the SREBP inhibitor, fatostatin, enhanced the suppression of NPC metastasis. Our results indicated that interventions targeting ANRIL‐shZBTB7A and SREBP inhibitors can effectively disrupt lipid metabolism and impair the invasive and metastatic properties of NPC cells. These findings provide valuable insights into the potential experimental strategies for inhibiting NPC metastasis.


  • Open Access

    Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region

    by Ruilan Lin, Ru Qin, Yunlong Zhang, Yao Guan, Boheng Wu, Shangyang Li, Shenhong Qu, Yulin Yuan

    Background: This study aims to assess the diagnostic value of the Epstein-Barr virus (EBV) BNLF2b antibody(P85-Ab), alone or in combination with VCA-IgA, Rta-IgG, and Zta-IgA antibodies, in the context of nasopharyngeal carcinoma (NPC). Methods: The study included 100 NPC patients and 100 healthy controls. Chemiluminescent microparticle immunoassay was utilized to measure P85-Ab levels in the serum samples of both NPC patients and healthy controls. Additionally, the ELISA method was employed to detect serum levels of VCA-IgA, Rta-IgG, and Zta-IgA antibodies. The study analyzed the roles of serum P85-Ab in conjunction with VCA-IgA, Rta-IgG, and Zta-IgA antibodies in the diagnosis of NPC. Results: Serum levels of P85-Ab, VCA-IgA, Rta-IgG, and Zta-IgA antibodies in NPC patients were significantly higher than those in the normal control group (P < 0.05). The area under the receiver operating characteristic curve (AUC) for individual diagnosis of NPC using serum P85-Ab, VCA-IgA, Rta-IgG, and Zta-IgA antibodies were 0.964, 0.916, 0.838, and 0.840, respectively. The AUC for the combined detection of the four markers in diagnosing NPC was 0.996, indicating the optimal diagnostic value of the combined detection. Conclusion: The combined detection of P85-Ab with VCA-IgA, Rta-IgG, and Zta-IgA antibodies demonstrates high diagnostic value for nasopharyngeal carcinoma. Serum P85-Ab may serve as a potential marker for the diagnosis of NPC.


  • Open Access

    STIM1 signaling modulates invasive phenotypic plasticity by regulating calpain-dependent cleavage of integrin-β4 in nasopharyngeal carcinoma cells

    by Weiming Deng, Wenlin Huang, Yujuan Huang, Lihong Huang, Linsong Ye, Fei Liu, Min Li, Jingjin Weng, Qian He, Jinyan Zhang, et al.

    Stromal interaction molecule 1 (STIM1)-mediated Ca2+ signaling modulates the malignant features of nasopharyngeal carcinoma (NPC), a unique Epstein-Barr virus (EBV)-associated human malignancy. Integrin-β4 is involved in EBV-promoted motility in NPC cells. However, the underlying mechanism through which STIM1 signaling manipulates the invasive characteristics of NPC cells and the implication of integrin-β4 remains elusive. The present study aimed to characterize the role of integrin-β4 in the phenotypic plasticity for the epithelial-mesenchymal and mesenchymal-epithelial transitions (EMT and MET), and determine whether STIM1 signaling enhances invasive potential by modulating integrin-β4 cleavage in NPC cells. Western blotting of epithelial and mesenchymal markers, cell migration and colony formation assays were performed to evaluate the EGF-stimulated EMT and laminin-induced MET in vitro. A zebrafish xenograft model was employed to elucidate the proliferation of transplanted NPC cell spheroids in vivo. A tail vein injection-lung metastasis mouse model was utilized to determine the capacity for distant metastatic colonization of NPC cells. Immunohistochemical analysis was conducted to detect the expression level of integrin-β4 in NPC tissues. Integrin-β4 was required for the bi-directional epithelial-mesenchymal transition in NPC cells. Silencing of integrin-β4 inhibited cell migration and clonogenicity in vitro, reduced clonal expansion of tumor cell clusters in zebrafishes, and eliminated distant metastatic colonization in mice. STIM1 Ca2+ signaling modulated the redistribution of integrin-β4 in migrating NPC cells. Mechanistically, STIM1-mediated Ca2+ influx enhanced aggregation of integrin-β4 at the cell membranes by promoting the calpain-dependent cleavage of integrin-β4. Clinically, we confirmed that integrin-β4 was highly expressed in primary tumors and cervical lymph node metastases. STIM1 signaling promotes invasiveness by enabling accelerated subcellular integrin-β4 redistribution, which is essential for maintaining the invasive plasticity of NPC cells.


  • Open Access

    Impact of PDCA cycle-driven nutritional support on serum biomarkers and quality of life in nasopharyngeal carcinoma patients undergoing radiotherapy

    by Weiming Xiong, Jinying Mo, Jingjin Weng, Yongli Wang, Jiazhang Wei, Linsong Ye, Min Li, Shenhong Qu

    Background: This study aimed to assess the effectiveness of nutritional support guided by the PDCA (Plan-Do-Check-Act) cycle management model in nasopharyngeal carcinoma (NPC) patients undergoing radiotherapy. Methods: A total of 100 NPC patients between December 2021 and October 2023 were randomly assigned to two groups: an observation group (OG, n = 50) and a control group (CG, n = 50). The CG received routine nutritional support, while the OG received nutritional support based on the PDCA cycle. Key outcomes included blood nutritional biomarkers, quality of life (QoL), incidence of adverse reactions (ARs), and clinical efficacy. Results: Post-treatment analysis showed that the OG had a significantly higher total effective rate (72%) compared to the CG (38%) (P< 0.05). The OG also showed higher albumin, prealbumin, and total protein levels and lower CRP levels after treatment. The OG significantly improved cognitive, role, social, physical, and emotional functioning (P< 0.05). The AR rate was considerably lower in the OG (20%) compared to the CG (36%) (P< 0.05). Conclusions: These results suggest that PDCA cycle-based nutritional support enhances clinical efficacy and QoL, reduces nutritional risks and adverse reactions and improves overall safety in NPC patients undergoing radiotherapy. Serum markers like serum iron, ferritin, prealbumin, and CRP effectively monitored the impact of nutritional interventions on patients' nutritional and inflammatory status.

  • Open Access

    Bibliometric analysis reveals the research hotspots and trends of nasopharyngeal carcinoma immunotherapy

    by Gang Wang, Xiaosu Zou, Jingjin Weng, Guiping Lan, Min Li, Jiazhang Wei, Wenqian Nong, Qicong Chen, Weiwei Miao, Honglin Luo, et al.

    Immunotherapy is a promising strategy for nasopharyngeal carcinoma (NPC), a common and aggressive malignancy with poor prognosis. However, the literature lacks a comprehensive and objective overview of the current research status and trends of immunotherapy-related fields in NPC. We performed a bibliometric analysis of 513 original articles and reviews in English on immunotherapy for NPC from the Web of Science Core Collection database, using CiteSpace and Bibliometrix software tools. We visualized the development trend of publications, the distribution of countries/regions, the co-occurrence of keywords, the collaboration and citation of authors, the citation of journals, the evolution of topics, and the thematic map. We found that the publication volume increased sharply after 2017, with China as the main contributor and leader, the US as an important partner, and the Netherlands as a potential innovator. The research focused on immune checkpoint inhibitors and cell therapy, which were also the hotspots of clinical trials. Tumor microenvironment, immune infiltration, multicenter studies, and novel immunotherapy were the frontier topics and the key challenges for future research. CD137l-DC, lymphoma, and chimeric antigen receptor were emerging topics with good prospects. Our study provides a valuable insight into the research status and trends of immunotherapy for NPC, which may guide future research directions and clinical applications.


  • Open Access

    The relationship and clinical significance of lactylation modification in digestive system tumors

    by Gang Wang, Xiaosu Zou, Qicong Chen, Wenqian Nong, Weiwei Miao, Honglin Luo, Shenhong Qu

    Lactylation, an emerging post-translational modification, plays a pivotal role in the initiation and progression of digestive system tumors. This study presents a comprehensive review of lactylation in digestive system tumors, underscoring its critical involvement in tumor development and progression. By focusing on metabolic reprogramming, modulation of the tumor microenvironment, and the molecular mechanisms regulating tumor progression, the potential of targeting lactylation as a therapeutic strategy is highlighted. The research reveals that lactylation participates in gene expression regulation and cell signaling by affecting the post-translational states of histones and non-histone proteins, thereby influencing metabolic pathways and immune evasion mechanisms in tumor cells. Furthermore, this study assesses the feasibility of lactylation as a therapeutic target, providing insights for clinical treatment of gastrointestinal cancers. Future research should concentrate on elucidating the mechanisms of lactylation, developing efficient lactylation inhibitors, and validating their therapeutic efficacy in clinical trials, which could transform current cancer treatment and immunotherapy approaches. In summary, this review emphasizes the crucial role of lactylation in tumorigenesis and progression through a detailed analysis of its molecular mechanisms and clinical significance.